<DOC>
	<DOCNO>NCT01423890</DOCNO>
	<brief_summary>A prospective population-based cohort study conduct Ontario evaluate whether performance Oncotype DX® change treatment recommend treatment receive woman men node negative , ER positive breast cancer receiving ( receive ) endocrine therapy candidate chemotherapy . One thousand eligible consent woman men tumor tissue specimen send Genomic Health Oncotype DX® assay perform .</brief_summary>
	<brief_title>A Prospective Cohort Study Evaluate Oncotype DX® Test Early Stage Breast Cancer</brief_title>
	<detailed_description>The evidence support adoption Oncotype DX® relatively weak criterion use Ontario Health Technology Advisory Committee ( OHTAC ) . There one small publish prospective study report Oncotype DX® change clinical management . The economic model estimate potential advantage use Oncotype DX® guide treatment strategy may overestimate benefit assume patient tumor &gt; 1cm absence Oncotype DX® test would receive chemotherapy addition tamoxifen , magnitude benefit chemotherapy tamoxifen relatively large , i.e . reduces recurrence risk 74 % associate absolute benefit 28 % . ( The benefit come one trial apply patient ) . It estimate 3,300 incident case node negative , ER positive , HER2 neu negative tumor annually Ontario , important evaluate adoption test decision make Ontario .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women men histologic evidence invasive breast cancer ( ductal , lobular mixed disease ) . Surgical resection include breast conserving surgery modify radical mastectomy simple mastectomy , within last four month . Axillary lymph node assess tumor : ( ) sentinel node biopsy , ( ii ) axillary node dissection , ( iii ) Axillary lymph node assessment negative cancer , positive micrometastases ( i.e. , cancer &lt; 2mm H &amp; E stain ) . Tumor estrogen receptor ( ER ) positive . Receiving receive adjuvant endocrine therapy ( i.e. , tamoxifen aromatase inhibitor ) . Being consider adjuvant chemotherapy . Axillary lymph node positive cancer . Patients inoperable locally advanced breast cancer . Metastatic breast cancer , include local ipsilateral recurrence . HER2 neu positive . Physician/Patient unwilling comply study protocol . Inability provide inform consent ( e.g . dementia severe cognitive impairment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Oncotype DX</keyword>
	<keyword>Adjuvant ! Online</keyword>
	<keyword>Decisional Conflict Scale</keyword>
</DOC>